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Background: In a recent study utilizing a saline-lavaged adult rabbit model, we described a 
significant improvement in systemic oxygenation and pulmonary shunt after the instillation of 
a novel synthetic peptide-containing surfactant, Synsurf. Respiratory distress syndrome in the 
preterm lamb more closely resembles that of the human infant, as their blood gas, pH values, 
and lung mechanics deteriorate dramatically from birth despite ventilator support. Moreover, 
premature lambs have lungs which are mechanically unstable, with the advantage of being 
able to measure multiple variables over extended periods. Our objective in this study was to 
investigate if Synsurf leads to improved systemic oxygenation, lung mechanics, and histology 
in comparison to the commercially available porcine-derived lung surfactant Curosurf® when 
administered before first breath in a preterm lamb model.
Materials and methods: A Cesarean section was performed under general anesthesia 
on 18 time-dated pregnant Dohne Merino ewes at 129–130 days gestation. The premature 
lambs were delivered and ventilated with an expiratory tidal volume of 6–8 mL/kg for the 
first 30 minutes and thereafter at 8–10 mL/kg. In a randomized controlled trial, the two 
surfactants tested were Synsurf and Curosurf®, both at a dose of 100 mg/kg phospholipids 
(1,2-dipalmitoyl-L-α-phosphatidylcholine; 90% in Synsurf, 40% in Curosurf®). A control 
group of animals was treated with normal saline. Measurements of physiological variables, 
blood gases, and lung mechanics were made before and after surfactant and saline replace-
ment and at 15, 30, 45, 60, 90, 120, 180, 240 and 300 minutes after treatment. The study 
continued for 5 hours.
Results: Surfactant treatment led to a significant improvement in oxygenation within 30 minutes, 
with the Synsurf group and the Curosurf® group having significantly higher ratios between  arterial 
partial pressure of oxygen/fraction of inspired oxygen (PaO
2
/FiO
2
; P = 0.021) compared to that 
of the control (saline-treated) animals. Dynamic compliance improved in the three groups over 
time, with no intergroup differences. All of the surfactant-treated animals survived, and one 
in the saline group died before the study ended. Histology between groups was not different, 
showing mild–moderate injury patterns.
Discussion: Treatment with surfactants before first breath clearly resulted in improved systemic 
oxygenation within 30 minutes of instillation. Both Synsurf- and Curosurf®-treated animals 
experienced similar and more sustained improvement in oxygenation and decreased calculated 
shunt compared to saline-treated animals.
Keywords: respiratory distress syndrome, preterm lambs, pulmonary surfactant, 
gas exchange, oxygenation
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Introduction
The essential role of hydrophobic surfactant proteins SP-B 
and SP-C in natural surfactant function has been well 
described.1–3 Increasingly, the recombinant production 
of these hydrophobic proteins has been the focus for the 
 development of synthetic surfactants, especially after the 
protein-free synthetic surfactants were shown to perform 
somewhat inferiorly to mammalian-derived surfactants in 
the acute management of new-born infants with respiratory 
distress syndrome (RDS).4 Some in vitro studies have shown 
that mixtures of phospholipids with SP-B yield surfactants 
that are more efficacious than SP-C-based surfactants, 
with SP-B-based preparations displaying markedly lower 
susceptibility to fibrinogen inhibition than SP-C prepara-
tions.5,6 However, head-to-head trials comparing various 
animal-derived surfactants that provide varying amounts 
of SP-B or phospholipids have shown minor differences 
in outcomes related to the management of RDS or none at 
all. Post hoc analysis of data from one study showed bet-
ter survival using a high initial dose of Curosurf® (Chiesi 
Farmaceutici SpA, Parma, Italy) when compared with 
Survanta® (Abbott Laboratories, Abbott Park, North Chi-
cago, IL, USA).7 New surfactant  preparations that include 
peptides or whole proteins that mimic endogenous surfac-
tant protein have recently been developed and tested.8–10 
A new-generation synthetic surfactant that contains a 
 peptide mimicking the action of SP-B, Surfaxin (Discovery 
Laboratories,  Warrington, PA, USA), performed better than 
a protein-free synthetic surfactant (Exosurf; GlaxoKline-
Smith, Brentford, UK), and similarly to animal-derived 
surfactants (Survanta® and Curosurf®).11 A Cochrane review 
identified two studies that compared protein- containing 
synthetic surfactants to animal-derived surfactant prepara-
tions. In a meta-analysis of these two studies, infants who 
received protein-containing synthetic surfactant compared 
to animal-derived surfactant extract did not demonstrate 
significant differences in primary outcomes, ie, death and 
chronic lung disease.12
In a recent study utilizing a saline-lavaged adult rabbit 
model, we described a significant improvement in systemic 
oxygenation and pulmonary shunt after the instillation of a 
novel synthetic peptide-containing surfactant, Synsurf.8 Our 
objective in the present study was to investigate if Synsurf 
leads to improved systemic oxygenation, lung mechanics, 
and histology in comparison to the commercially available 
porcine-derived lung surfactant Curosurf® when adminis-
tered before first breath in a preterm lamb model.
Materials and methods
surfactant preparations
Synsurf was prepared as described previously.8 Briefly, 
dipalmitoylphosphatidylcholine (DPPC), hexadecanol, and 
phosphatidylglycerol were mixed in a 10:1.1:1 ratio (w/w) in 
chloroform. The organic solvent was then removed by rotary 
evaporation, and the mixture was dried under a continu-
ous stream of nitrogen at room temperature. Poly-L-lysine 
(∼100–120 residues) was mixed with poly-L-glutamate 
(∼80 residues) and incubated at 37°C in 0.1 M NaCl to give a 
complex which is 50% neutralized. The dried phospholipid 
film was then hydrated with the polymer mixture (3% by 
weight of the phospholipid concentration) and gently mixed 
in the presence of glass beads. The mixture was ultrasonicated 
on ice under a stream of nitrogen (20 watts for 7 × 13 seconds 
at 60-second intervals). Thereafter, 24 mg of tyloxapol was 
added to the preparation, and the tube was sealed under nitro-
gen before use. The molecular structure of the two-stranded 
polymer and possible interactions with DPPC is shown in 
Figure 1. Both Synsurf and Curosurf® (Chiesi Farmaceutici 
SpA) were used at a dose of 100 mg/kg phospholipids.
Delivery and ventilation of lambs
Animal care and experimental procedures were performed 
under approval from the Faculty of Medicine and Health 
Sciences Research Committee of Stellenbosch University. 
Eighteen time-dated pregnant Dohne Merino ewes at 
129–130 days gestation (normal gestation 148–154 days) 
were anesthetized with intravenous 2.5% thiopental sodium, 
intubated, and mechanically ventilated with inhalation 
of 1%–2% halothane in oxygen. A Cesarean section was 
performed, and the fetal head and neck were exteriorized. 
To withdraw lung fluid, subcutaneous lignocaine (2%) was 
infiltrated into the midtracheal region with a 24-gauge needle 
attached to a syringe. Ten to 15 mL of fetal lung fluid was 
sampled to determine lung maturity (lamellar body count) 
and to remove excessive lung fluid. A neck incision was 
then made, followed by a tracheotomy. An uncuffed 4 mm or 
4.5 mm endotracheal tube was placed and advanced to 4 cm. 
The umbilical cord was cut, the fetus was then delivered, 
weighed, dried, and placed in a supine position on warming 
pads under a radiant warmer. Within 2 minutes after umbilical 
cord ligation, before first breath, two of the groups received 
100 mg/kg of either Synsurf or Curosurf®. The third group 
(control) received normal saline. The lambs were anesthe-
tized and sedated with continuous infusion of midazolam 
(Dormicum® [Roche, Basel, Switzerland], 0.1 mg/kg/hour) 
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and morphine (5–10 µg/kg/hour). Supplemental intermit-
tent ketamine dosages (10 mg/kg) were administered when 
spontaneous breathing was observed on the flow curves. Ani-
mals were paralyzed with intravenous pancuronium bromide 
(0.1 mg/kg, hourly). A rectal thermistor was placed to con-
tinuously monitor body temperature, which was maintained 
at 38°C–39°C. To minimize lung injury, ventilation during 
the first 30 minutes after birth was initiated with time-cycled, 
pressure-limited assist control ventilation (AVEA® ventilator 
system; CareFusion, San Diego, CA, USA). The expiratory 
tidal volume was set at 6–8 mL/kg and was then increased 
to 8–10 mL/kg. Hereafter, the ventilator settings were held 
constant throughout the study at an inspired O
2
 fraction 
(FiO
2
) of 1.0, a rate of 50 breaths/minute, an inspiratory 
time of 0.50 seconds, and a positive end-expiratory pressure 
of 4 cm H
2
O. Immediately after ventilation was started, a 5 
French catheter was passed via the femoral artery into the 
aorta for monitoring blood pressure and heart rate and for 
blood gas measurements. Each lamb received a continuous 
infusion of 5% dextrose water that was begun at the start of 
the study. Lambs were assigned to one of three groups (six 
lambs/group). Measurements of physiological variables, 
blood gases, and lung mechanics (tidal volume, dynamic 
compliance of the respiratory system [C
dyn
]) were made 
before and after surfactant and saline replacement and at 15, 
30, 45, 60, 90, 120, 180, 240 and 300 minutes after treatment. 
After 5 hours, all live animals were killed by lethal injection 
of intra-arterial 15% potassium chloride. The chest wall 
was opened and quasistatic maximal inspiratory capacity 
of the intact lung at 35 cm H
2
O peak plateau pressure and 
positive end-expiratory pressure of zero was determined 
after exsanguination. In lambs without a pneumothorax, 
the lung (right lung caudal, middle, and cranial lobes) was 
then gravitationally filled with formaldehyde (4%) and 
inflated under a constant pressure of 25 cm H
2
O. This lung 
was used for histology and morphometry. Total lung water 
was determined after the animals were killed by calculating 
the difference between the wet weight minus the weight of 
the lung exposed to 80°C until the weight was constant for 
48 hours (∼4–6 days). It is expressed as the lung wet weight/
dry weight ratio.
statistical analysis
STATISTICA version 10 (StatSoft, Tulsa, OK, USA) and 
GraphPad Prism 5 (GraphPad Software Inc, La Jolla, CA, 
USA) were used to determine comparability of the experimental 
groups before and after surfactant instillation. Changes of vari-
ables between the groups were analyzed with one-way analysis 
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of variance (and nonparametric). The Kruskal–Wallis test and 
Dunn’s multiple comparison test were used as the discriminat-
ing post-test. Data are expressed as mean ± standard deviation. 
Significant differences were accepted at P-values , 0.05.
Mean linear intercept analysis
The mean linear intercept as an indicator of alveolar airspace 
size was calculated from counting lines of defined length as 
previously described by Dunnill.13 Briefly, the lines were 
randomly placed on every lung section, and the number of 
intersections crossing the lines were counted. The mean 
linear intercept is calculated from the length of the lines 
multiplied by the number of lines, divided by the sum of all 
counted intercepts.
Results
respiratory outcomes
At randomization, arterial blood gases, ventilator indexes, 
and hemodynamic variables were similar for all three 
groups. Table 1 gives an overall summary of the pretreat-
ment parameters of the three groups. All lambs were severely 
surfactant- deficient as their lamellar body counts were less than 
15,000/µL and lecithin/sphingomyelin ratios were less than 2. 
The surfactant deficiency was further reflected in the overall 
low mean C
dyn
 (mean for n = 18, 0.31 ± 0.09 mL/cmH
2
O ⋅ kg) 
and poor oxygenation status as reflected by a low arte-
rial/alveolar ratio (mean for n = 18, 0.03 ± 0.01) and a 
high oxygenation index (mean for n = 18, 53.69 ± 32.1). 
There were no significant differences between the three groups. 
Following instillation of surfactant, the Synsurf group and 
the Curosurf® group experienced significant improvement in 
oxygenation (arterial partial pressure of oxygen [PaO
2
]/FiO
2
 
ratio, P = 0.021) within 30 minutes (Table 2 and Figure 2A), 
compared to that of the saline-treated animals. Moreover, 
both surfactant-treated groups showed better oxygenation 
over the time period of the study. For Synsurf-treated ani-
mals, oxygenation was significantly better compared to the 
saline-treated animals at timepoints 30, 45, 60, 90, 120 and 
180 minutes. With exception of the 120-minute timepoint, 
the finding was similar for the Curosurf® versus saline-treated 
Table 1 indexes, lung mechanics, cord blood gasses, and 
calculated shunt
Variable Synsurf  
(n = 6)
Curosurf®  
(n = 6)
Saline  
(n = 6)
l/s ratio 0.97 ± 0.09 0.97 ± 0.05 1.15 ± 0.09
lamellar body  
count/µl
5333 ± 3933 5500 ± 1049 5500 ± 2881
PaO2 (mmhg) 27.63 ± 9.3 19.25 ± 9.2 27.00 ± 9.0
PcO2 (mmhg) 43.80 ± 9.2 47.35 ± 11.5 50.11 ± 7.2
TcO2 (mmol/l) 26.57 ± 4.4 26.92 ± 1.5 27.15 ± 1.7
cdyn (ml/cmh2O ⋅ kg) 0.27 ± 0.06 0.31 ± 0.05 0.38 ± 0.12
a/a ratio 0.04 ± 0.02 0.03 ± 0.01 0.04 ± 0.01
ph 7.39 ± 0.07 7.34 ± 0.10 7.32 ± 0.07
Oi 44.06 ± 14.8 73.89 ± 48.2 43.11 ± 15.2
Qs/Qt 62.02 ± 7.0 67.62 ± 8.7 62.62 ± 7.7
Notes: Baseline measurements were compared using nonparametric Kruskal–
Wallis test. Data expressed as a mean ± standard deviation (t-test). curosurf ® 
manufactured by chiesi Farmaceutici spa, Parma, italy.
Abbreviations: a/a ratio, arterial/alveolar ratio; cdyn, dynamic respiratory 
compliance; l/s, lecithin/sphingomyelin; Oi, oxygenation index; PaO2, arterial partial 
pressure of O2; PcO2, arterial partial pressure of cO2; Qs/Qt, pulmonary shunt; 
TcO2, total cO2.
Table 2 Physiological variables, lung mechanics, and postnatal 
blood gasses
Variable Synsurf 
group  
(n = 6)
Curosurf® 
group  
(n = 6)
Saline 
group  
(n = 6)
Weight (kg) 3.4 ± 0.4 3.2 ± 0.5 3.4 ± 0.7
Tracheal fluid  
(ml/kg)
4.43 ± 1.6 3.34 ± 1.6 4.47 ± 1.8
Vte (ml/kg)
 30 min
 90 min
 180 min
 300 min
7.77 ± 0.4
8.88 ± 1.0
8.93 ± 0.9
8.45 ± 1.1
7.61 ± 0.6
9.48 ± 0.6
9.77 ± 0.5
9.43 ± 1.3
7.95 ± 1.0
9.28 ± 0.8
9.13 ± 0.5
9.46 ± 0.7
MaBP (mmhg)
 30 min
 90 min
 180 min
 300 min
59.17 ± 7.6
57.17 ± 5.0
53.83 ± 5.1
48.50 ± 5.8
62.50 ± 4.9
61.00 ± 8.0
58.33 ± 5.0
48.83 ± 9.9
63.67 ± 8.8
55.17 ± 1.2
50.67 ± 7.4
48.60 ± 4.3
PaO2/FiO2 (mmhg)
 30 min
 90 min
 180 min
 300 min
311.13 ± 102.73
245.59 ± 136.04
205.00 ± 155.96
288.88 ± 137.13
346.38 ± 126.40
265.13 ± 87.65
189.88 ± 113.22
133.75 ± 110.64
160.38 ± 89.11
117.30 ± 93.64
59.63 ± 43.96
190.90 ± 149.58
PacO2 (mmhg)
 30 min
 90 min
 180 min
 300 min
68.74 ± 24.4
45.69 ± 7.7
45.55 ± 8.0
52.73 ± 24.9
70.66 ± 17.6
53.08 ± 18.0
51.56 ± 19.3
63.50 ± 16.2
80.13 ± 27.0
52.28 ± 17.2
47.09 ± 19.9
54.39 ± 23.53
TcO2 (mmol/l)
 30 min
 90 min
 180 min
 300 min
24.7 ± 3.5
24.8 ± 2.3
25.8 ± 1.1
26.2 ± 2.3
26.4 ± 3.2
25.5 ± 2.0
24.1 ± 1.9
26.8 ± 3.4
25.2 ± 3.6
22.6 ± 2.8
22.6 ± 3.3
24.0 ± 2.5
cdyn (ml/cmh2O ⋅ kg)
 30 min
 90 min
 180 min
 300 min
0.34 ± 0.05
0.39 ± 0.06
0.43 ± 0.07
0.45 ± 0.09
0.34 ± 0.03
0.43 ± 0.04
0.48 ± 0.05
0.48 ± 0.05
0.33 ± 0.15
0.37 ± 0.08
0.39 ± 0.10
0.47 ± 0.07
Notes: Data expressed as mean ± standard deviation (t-test). Bolded PaO2/FiO2 
values reflect significant higher ratios (P = 0.021). curosurf ® manufactured by chiesi 
Farmaceutici spa, Parma, italy.
Abbreviations: cdyn, dynamic respiratory compliance; MaBP, mean arterial blood 
pressure; PacO2, arterial partial pressure of cO2; PaO2/FiO2, arterial partial pressure 
of oxygen/fraction of inspired oxygen ratio; TcO2, total cO2; Vte, expiratory tidal 
volume.
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animals. However, at 300 minutes the Synsurf-treated animals 
had a significantly better oxygenation status when compared 
to Curosurf® (P = 0.014863, determined by mixed model 
repeated measures analysis of variance). A decrease in calcu-
lated pulmonary shunt (time period 0–300 minutes; Figure 3) 
in the Synsurf, Curosurf®, and saline-treated group of animals 
was observed (intergroup differences: Synsurf 18.82 ± 16.19 
versus Curosurf® 22.35 ± 18.42, P = 0.09; and Synsurf versus 
saline 34.41 ± 12.52, P = 0.003; Friedman analysis of  variance). 
At 300 minutes the mean calculated value for Synsurf was 
18.44%, versus 36.29% and 32.63% for the Curosurf® group 
and the saline-treated group, respectively. Significant lower 
pulmonary shunt values for Synsurf-treated animals occurred 
at 180 minutes (P , 0.05, two-way analysis of variance, Syn-
surf versus the saline group) and at 300 minutes (P = 0.0002, 
t-test, Synsurf versus the saline group and the Curosurf®group). 
The arterial partial pressure of carbon dioxide (PaCO
2
) also 
decreased from about 70 mmHg to about 58 mmHg in the 
surfactant-treated animals (Figure 2B).
Pulmonary mechanics
To avoid compromising the effect of surfactant rescue treat-
ment and to minimize lung over-distension, initial ventilation 
with an expiratory tidal volume of 6–8 mL/kg and thereaf-
ter 8–10 mL/kg was used. As a consequence, we found no 
significant differences between the Synsurf and Curosurf® 
groups for expiratory tidal volumes (Figure 4A) as well 
as for the arterial PaCO
2
 values (Figure 2B) between the 
start of the study and at 300 minutes. Total C
dyn
 (Figure 4B) 
steadily increased in all of the study groups over time 
between timepoint 0 minutes (start of experiment) and 
300 minutes (P = 0.0012, P = 0.00026, and P = 0.0268 for 
Synsurf, Curosurf®, and saline, respectively). There were no 
significant intergroup differences at 300 minutes (Synsurf 
C
dyn
 0.45 ± 0.09, Curosurf® C
dyn
 0.48 ± 0.05, and saline C
dyn
 
0.47 ± 0.07). All of the surfactant-treated animals survived 
and one in the saline group died before the study ended. 
However, two lambs developed a pneumothorax during 
the study, one each in the saline group and Synsurf-treated 
group. Representative lungs in the three groups were used 
for quasistatic lung volume measurements, as determined 
0
0 30 60 90 120 150 180 210 240 270 300
50
100
150
200
250
300
350
400
450A
B
P
aO
2/
F
iO
2
Time (min)
0
0 30 60 90 120 150 180 210 240 270 300
2
40
60
80
100
P
aC
O
2 
(m
m
H
g
)
Time (min)
Treatment
Treatment
Synsurf Curosurf® Saline
Synsurf Curosurf® Saline
Figure 2 Time profiles for PaO2/FiO2 and PacO2. 
Notes: Time profile of oxygenation as depicted by a comparison of the sequential 
measurements of the ratios of arterial PaO2 to inspired oxygen fractions FiO2 
(A). Significant timepoint differences between the groups were analyzed by mixed 
model repeated measures analysis of variance and are described in the results. arterial 
PacO2 before and after treatment with synsurf or curosurf
® or saline (B). Values 
are shown as the mean ± standard deviation (t-test). Lambs were treated before first 
breath. curosurf ® manufactured by chiesi Farmaceutici spa, Parma, italy. 
Abbreviations: FiO2, fraction of inspired oxygen; PacO2, arterial partial pressure 
of cO2; PaO2, arterial partial pressure of oxygen.
70
60
50
40
30
20
10
0
0 30 60 90 120 150 180 210 240 270 300
Time (min)
Treatment
Synsurf
Q
s/
Q
t
Curosurf® Saline
Figure 3 Time profile of a comparison of pulmonary shunt (Qs/Qt) between lamb 
groups before and after administration of synsurf or curosurf® or saline. 
Notes: Values are shown as the mean ± standard deviation. Qs/Qt was lower for 
the synsurf group at 180 minutes (P , 0.05 by two-way analysis of variance, versus 
saline) and at 300 minutes (P = 0.0002, t-test, versus saline and curosurf® groups). 
curosurf ® manufactured by chiesi Farmaceutici spa, Parma, italy.
Drug Design, Development and Therapy 2013:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
910
van Zyl and smith
in the open-chest state for maximal inspiratory capacity. 
Values were 36.22 ± 10.21 mL/kg for a saline-treated lamb, 
33.95 ± 8.03 mL/kg for a Curosurf®-treated lamb, and 
32.96 ± 1.98 mL/kg for a Synsurf-treated lamb. There were 
no statistical intergroup differences.
Indicators of inflammation
Systemic inflammation
The cord blood had the typical lymphocytosis of fetal blood 
for all study groups (Table 3). After 5 hours of ventilation the 
numbers of white blood cells changed significantly only in the 
Curosurf®-treatment group. In this group, the mean peripheral 
white blood cell count rose from 1.2 to 2.5 (P = 0.0236), with 
significant intragroup increase in the neutrophil count. In all 
of the groups, the predominant shift from a lymphocytosis 
in cord blood to a neutrophilic predominance occurred after 
5 hours of ventilation. There were, however, no significant 
differences between the groups.
Lung inflammation and appearance and morphology
The macroscopic appearance of lungs of the majority of 
lambs was categorized as mild, moderate, or severe (wide-
spread) atelectasis as reflected by the extent of visible dark 
areas (Figure 5). There were no clear visible group differ-
ences with regard to the distribution of the injury. In almost 
all of the groups, except for one lamb in the Curosurf® 
group, the posterior regions of the lungs, especially the 
lower and inferior regions of the lobes, showed atelectasis 
(dark areas) with or without small hemorrhages. Of the 
Synsurf-treated lambs, two had mild (Figure 5A) and four 
had moderate atelectasis (Figure 5B). Of the Curosurf®-
treated lambs, one had a normal, uniform, expanded lung 
appearance (Figure 5C), three had mild (Figure 5D), and 
two had moderate (Figure 5E) atelectasis. The lungs of only 
four saline-treated animals were available; one showed mild 
atelectasis (Figure 5F), two had moderate (Figure 5G), and 
one had severe (Figure 5H) atelectasis. Representing the 
average size of the alveoli, measurements of the mean linear 
intercepts (Figure 6) of the Curosurf® group and the Synsurf 
group were higher than that of the saline group. However, 
this was not statistically significant (intergroup differ-
ences: Synsurf 48.68 ± 5.16 versus Curosurf® 49.82 ± 8.78, 
P = 0.804; Synsurf versus saline 43.10 ± 3.79, P = 0.115; 
and Curosurf® versus saline, P = 0.192), and therefore 
excluded alveolar damage as a result of differences in 
applied volume/pressure during ventilation. Enlargement 
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Table 3 cord and peripheral white blood cell (WBc) and 
differential count
Cell type Synsurf  
(n = 6)
Curosurf®  
(n = 6)
Saline  
(n = 6)
Cord blood
WBc × 109/l 
% neutrophils 
% lymphocytes
1.9 ± 1.3
20.3 ± 15.2
65.9 ± 12.6
1.2 ± 0.7
24.9 ± 25.2
65.9 ± 21.1
1.9 ± 1.3
20.3 ± 15.2
65.9 ± 12.6
Count at 300 min
WBc × 109/l 
% neutrophils 
% lymphocytes
1.8 ± 1.7
42.8 ± 38.7
52.6 ± 35.5
2.5 ± 2.1
63.5 ± 23.1*
31.8 ± 23.7
1.8 ± 1.7
42.8 ± 38.7
52.6 ± 35.5
Notes: Data expressed as mean ± standard deviation, and *P , 0.05 by t-test. 
curosurf ® manufactured by chiesi Farmaceutici spa, Parma, italy.
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Calculations for postmortem lung water content, 
expressed as the lung wet weight/dry weight ratio (Synsurf 
6.23 ± 0.65, Curosurf® 5.67 ± 1.12, and saline 6.49 ± 1.57), 
showed no significant difference between any of the groups.
Discussion
We have demonstrated that a novel synthetic peptide-
containing surfactant (Synsurf), resulted in a more sus-
tained, improved oxygenation response compared to that of 
Curosurf®- or saline-treated premature lambs when treated 
before first breath.
Commercially available surfactants for replacement 
therapy are still mainly mammalian-derived, and their 
superiority over nonprotein-containing surfactants in the 
treatment of neonatal RDS has repeatedly been shown.12,14,15 
More recently, synthetic formulations containing an SP-C 
and/or SP-B analog have been developed and tested against 
mammalian-derived surfactants. Davis et al evaluated the 
efficacy of recombinant SP-C surfactant against natural sheep 
surfactant in vitro and in vivo using ventilated preterm lambs 
Saline SynsurfCurosurf®
20
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t 
(µ
m
)
40
60
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(n = 5)(n = 6)
Figure 6 Mean linear intercepts of airspaces for synsurf-, curosurf®-, and saline-
treated animals. 
Notes: Values are shown as mean ± standard error of the mean. Within the 
groups, the mean linear intercepts values were not statistically significantly different. 
curosurf ® manufactured by chiesi Farmaceutici spa, Parma, italy.
Figure 5 representative photographs of the appearance of lungs of synsurf- (A and B), curosurf®- (C–E), and saline-treated lambs (F–H). 
Notes: Dark color in animal lungs demonstrates injured/atelectatic areas. (A) mild in 2, (B) moderate in 4, (C) normal uniform expanded lung in 1, (D) mild in 3, (E) 
moderate in 2, (F) mild in 1, (G) moderate in 2, (H) severe in 1. curosurf ® manufactured by chiesi Farmaceutici spa, Parma, italy.
of histomorphology microscopic images (Figure 7) in the 
different groups showed no accumulation of alveolar mac-
rophages or white blood cells in the alveoli of the animals 
that received Curosurf® or Synsurf.
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and rabbits.16 They found that both surfactants were sensitive 
to inhibition by plasma and had similar lung mechanics, lung 
volume measurement, and indicators of lung injury. Interest-
ingly, a synthetic formulation (CHF5633) developed by Chiesi 
Farmaceutici SpA was recently compared with Survanta®, 
but not with Curosurf®, in extremely premature lambs (day 
124).10 The authors found that the SP-B/SP-C analog-con-
taining synthetic surfactant (200 mg/kg CHF5633) improved 
lung functions (tidal volumes at 2 minutes and dynamic lung 
compliance at 300 minutes) over that of Survanta® (100 mg/
kg). Both surfactant-treated groups showed large variations 
in alveolar size, with patchy atelectasis in the peripheral lung 
and similar degrees of lung inflammation at 5 hours.
Of all the protein components in pulmonary surfactant, 
SP-B and SP-C have an essential function in the spreading, 
adsorption, and stability of surfactant lipids. Fourier trans-
form infrared spectroscopy as well as infrared studies of por-
cine SP-B demonstrate that it possesses approximately 45% 
α-helical content, four amphipathic helices, and a β-sheet 
secondary structure (22%) interacting with areas of the phos-
pholipid bilayers.17,18 Various research groups have chemi-
cally prepared peptides with sequences based on SP-B.19,20 
Recently, the successful treatment of preterm infants with 
RDS was demonstrated with a peptide/phospholipid mixture 
KL
4
-surfactant prepared by Cochrane et al.9 This peptide, that 
possibly mimics the pattern of hydrophobic and hydrophilic 
residues in SP-B, is 21 amino acids long and contains five 
basic lysine (hydrophilic) residues, which interact with the 
negative charges of phospholipid polar head groups, and 16 
leucine (hydrophobic) residues that interact with the acyl side 
chains of the phospholipids.21–23 Moreover, it was designed 
with the intent to stabilize the phospholipid bilayer through 
its interaction with lipid head groups and portions of the 
fatty acid acyl chains. An initial study on the mechanism 
of interaction of KL
4
 peptide with phospholipid multilayers 
showed that it predominantly has α-helical content with a 
transmembrane orientation in lipid multilayers.21 However, 
in follow up studies it was shown that with DPPC films, the 
peptide adopted an antiparallel β-sheet structure.9
In our experiments, we reasoned that the polypeptide poly-
L-lysine, which is widely used in membrane research due to 
its interaction with acidic lipids, was worth studying as a KL
4
 
alternative. To test this idea, poly-L-lysine (∼100–120 resi-
dues) was mixed with poly-L-glutamic acid (∼80 residues) to 
give a complex (∼50% neutralisation) which is held together 
by strong electrostatic interaction (Figure 1). The rationale 
behind using polymers of poly-L-lysine complexed with poly-
L-glutamic acid was to have a two-stranded polymer contain-
ing a percentage of basic lysyl side chains participating in 
the formation of protein-lipid bonds, as well as some degree 
of hydrophobicity in the neutralized double-stranded portion 
of the molecule. It should be noted that reports indicate that 
electrostatic binding is coupled with hydrophobic effects in 
protein–lipid bonding and that electrostatic interaction pre-
cedes hydrophobic interaction.24,25 Moreover, poly-L-lysine 
also becomes increasingly helical with charge cancellation 
above 50%.26 At present, in preliminary experiments using 
Fourier transform infrared spectroscopy (van Zyl, unpub-
lished data, 2012), we have found results which suggest the 
existence of molecular zipper-like properties of poly-L-lysine 
and poly-L-glutamic acid, which was first described by 
Dzwolac and Marszalek.27 In these preliminary experiments, 
at neutral pD (experiments were carried out in D
2
O), we also 
found that the two form sequenceless poly-L-lysine–poly-
L-glutamic acid polymers in the random coil conformation 
(amide I′ band) self-assemble to form an antiparallel β-sheet 
with a characteristic splitting of the amide I′ band into a major 
and minor spectral component. However, a persisting 
amide I′ band still reflected residual loose chains (random 
coil  characteristics). At present, we suggest that these chains 
Figure 7 lung histology findings in representative animals of each treatment group. 
Notes: staining was done with hematoxylin and eosin. Original magnification × 40. localized areas of parenchymal damage occurred in the lungs of the curosurf®- and 
synsurf-treated groups (arrows) and are surrounded by normal parenchyma. no such damage is visible in the lungs of the saline group. scale bar: 2 µm. curosurf® 
manufactured by chiesi Farmaceutici spa, Parma, italy.
Synsurf Curosurf® Saline
2 µm
2 µm 2 µm
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of the polymer mixture will favor the exposure of the basic-
charged surface groups on the lysine side chains, whereby 
the construct could interact flexibly with other molecules 
such as phosphatidyl glycerol to perform a functional role in 
phospholipid monolayers. Furthermore, in agreement with 
other reports, we also assume that part of the beneficial effect 
of poly-L-lysine could relate to the interaction of the charged 
lysine amino groups with the anionic lipid headgroups and the 
ability to dehydrate the lipid bilayers.28,29 Furthermore, from 
the finding that positive charges are important for maintain-
ing the structure and function of SP-C,30,31 the argument can 
be made that the overall positive character of poly-L-lysine 
residues in Synsurf could contribute to the mimicking of 
SP-C structural and/or functional properties. This could also 
facilitate the action of Synsurf in our preterm lamb study, as 
it was shown that in the presence of phosphatidylglycerol, 
SP-C decreased the energy barrier limiting the adsorption of 
phospholipids to the air/liquid interface, possibly by introduc-
ing electrostatic interactions. As to the exact mechanism of 
action of the poly-L-lysine–poly-L-glutamic acid construct, 
further studies are in progress.
The recently developed Synsurf was also tested earlier, 
in vivo in an adult rabbit saline-lavaged model.8 In that 
study, we showed significant improvement in oxygenation 
and pulmonary shunt in the group of animals treated with 
Synsurf. The premature lamb model is an alternative test 
system, with a clinical and pathological course similar to 
that described for preterm newborns with RDS. We therefore 
conducted the present randomized trial to compare systemic 
oxygenation and lung mechanics in surfactant-deficient pre-
term lambs after treatment with either Synsurf (synthetic) 
or porcine-derived Curosurf® (natural) and saline as control 
before first breath.
We removed 10–20 mL/kg lung fluid before instilling 
vehicle and initiating ventilation in order to avoid ventila-
tion on top of the fluid volume and thus injuring the lung. 
Furthermore, vehicle at equivalent dosages was administered 
as bolus before first breath in order to facilitate more uniform 
spreading, followed by ventilation with lower tidal volume 
ventilation for the first 30 minutes, again to minimize injuri-
ous ventilation.32 Despite attempts to improve distribution 
of surfactant in a uniform manner, inhomogeneity probably 
still occurred during ventilation, as between gestation days 
120–130 the preterm lamb has lungs that are differentially 
matured, ie, the upper portions of the lungs are functionally 
more mature than the lower portions, and possibly receive 
better tidal volume ventilation.33 This was demonstrated by 
the distribution of visible dark areas of the excised lungs 
in the present study. Lambs were ventilated in the supine 
position, and it was evident that the dark areas which reflect 
atelectasis were mostly found in the posterior and posterior-
inferior regions of the lungs, with no significant differences 
in distribution between the groups. Nevertheless, before 
receiving surfactant, all of the lambs had significant surfac-
tant deficiency. Lambs that received surfactant responded 
with a marked increase in oxygenation and decrease in 
calculated shunt within 30 minutes of birth. Over the study 
period, replacement with Synsurf or Curosurf® resulted 
in a sustained, improved oxygenation response compared 
to saline-treated animals. The improved oxygenation was 
accompanied by a significantly improved calculated shunt 
over time in all three groups. However, at 300 minutes, 
Synsurf-treated lambs had a significantly higher PaO
2
/FiO
2
 
ratio accompanied by a lower calculated shunt (Synsurf 
versus saline at 180 minutes and Synsurf versus saline- and 
Curosurf®-treated lambs at 300 minutes; Figures 2A and 3). 
Notably, the Synsurf-treated lambs not only had a more 
sustained improvement in oxygenation, they also had lower 
tidal volumes and associated lower PaCO
2
 levels (Figures 4A 
and 2B), similar to what was described by Wolfson et al for 
lambs treated with lucinactant in their study.34
Furthermore, although C
dyn
 increased significantly only 
in the surfactant-treated groups, their time profiles did not 
differ significantly from that of saline-treated animals. In 
the present study, this trend (Figure 4B versus Figure 2B) 
is similar to the previous study that we conducted in adult 
rabbits, where we observed an increase in C
dyn
 in relation to 
a concurrent decrease in oxygenation over time.8
Our findings of modestly improved C
dyn
 values over the 
5-hour study period in all three study groups is of inter-
est because the changes in C
dyn
 were not accompanied by 
similar improvement in oxygenation. In fact, the Curosurf®-
treated lambs experienced the steadiest improvement in C
dyn
, 
yet their timepoint-corresponding PaO
2
/FiO
2
 ratios were 
decreasing. Only in the Synsurf-treated group at timepoint 
300 minutes did the improved PaO
2
/FiO
2
 ratio correlate 
significantly with their corresponding improved C
dyn
 values 
(R2 = 0.7047; P = 0.0366). A novel peptide-containing syn-
thetic surfactant, Surfaxin®, a SP-B mimetic, was recently 
approved by the US Food and Drug Administration. This 
surfactant was evaluated against porcine- and bovine-derived 
surfactants in the 125–128-day preterm lamb model in regard 
to its potential to modulate lung inflammation following 
initiation of mechanical ventilation.34 Surfactant treatment 
after commencing ventilation improved lung compliance 
to a similar extent compared to no surfactant treatment. In 
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agreement with our findings, the researchers also described 
“uncoupling” between sustained improved oxygenation and 
lung mechanics in lucinactant-treated animals. They sug-
gested that the uncoupling is due to the presence of SP-B 
or SP-B-mimicking peptide, KL4, in the surfactants, which 
support alveolar capillary shape by reducing surface tension, 
thereby improving pulmonary blood flow and shunt.35 Our 
study showed uncoupling between C
dyn
 and oxygenation and 
calculated intrapulmonary shunt, favoring the Synsurf-treated 
animals over that of Curosurf®- and saline-treated lambs.
Discrepancy between the time course of PaO
2
 and that of 
C
dyn
 was also described by Häfner et al in premature lambs at 
124–127 days gestation after treatment with bovine lung sur-
factant at 50 mg/kg body weight.36 Cummings et al reported 
contradictory findings in preterm lambs treated with a mam-
malian-derived product (calf lung surfactant extract) before 
first breath.37 They found significantly improved calculated 
compliance values, accompanied by improved oxygenation 
status in preterm lambs (127 days gestation) treated before 
commencing with artificial ventilation.  Interestingly, in that 
study, the superior oxygenation status and improved calcu-
lated compliance observed between lambs treated before 
first breath and those treated after 5 minutes of ventilation 
could not be explained by differences in histopathology. The 
authors therefore speculated that uneven surfactant distribu-
tion in an air-filled lung as compared to a liquid-filled lung 
could have produced the differences.
Does exogenous surfactant instilled before initiating ven-
tilation (prophylactic treatment) protect the immature lung 
against ventilation-induced lung injury? Contradictory and at 
times confusing evidence exists, with some research groups 
showing no significant injury, while others find an incom-
plete protective effect of natural surfactants that is linked to 
specific time frames after birth. For instance, Björklund et al 
studied immature lambs at 127 days gestation.38 They found 
that three of four lambs treated with high dosage Curosurf® 
before delivery (235 mg/kg and 265 mg/kg) or before first 
breath (200 mg/kg) showed no evidence of lung injury after 
4 hours of ventilation. In another study, the same research 
group administered Curosurf® (200 mg/kg) to lambs at vari-
ous time intervals after birth at 127 days gestation and then 
subjected the lambs to various inflation treatment groups.39 
Although the group did not publish clear quantitative histo-
logical data, they found that although surfactant treatment 
before first breath did not prevent lung injury, it did protect 
against severe lung injury. In contrast to these findings, 
Ikegami et al showed that extreme styles of ventilation had 
minimal effects on lung function, surfactant function, or 
metabolism in their study group of 131 ± 1 days preterm 
lambs treated with sheep surfactant before initiation of 
ventilation.40 Somewhat inexplicably, in that study, lambs 
ventilated with low-rate (15 breaths/min) and high tidal vol-
ume ventilation (15 mL/kg) had higher PaO
2
/FiO
2
 ratios for 
lower mean airway pressures at 24 hours of age compared to 
a high frequency ventilation and high rate positive pressure 
ventilation group. The same research group studied 126- or 
127-day gestation lambs and assessed tidal volume effects 
on surfactant treatment responses with the initiation of 
 ventilation.41 In one of their study arms, lambs were random-
ized to surfactant (Survanta® 100 mg/kg) treatment before 
initiation of ventilation and then ventilated with 6 mL/kg, 
12 mL/kg, or 20 mL/kg tidal volumes for 30 minutes and 
thereafter with 10 mL/kg tidal volumes to 6 hours of age. 
In contrast to their previous study findings, lambs initially 
ventilated with 6 mL/kg had lower dry-to-wet ratios and 
significantly less recovery of protein in alveolar washes 
compared to the 12 and 20 mL/kg tidal volume groups. The 
study showed that the combination of surfactant treatment at 
birth, followed by ventilation with tidal volumes ,12 mL/kg 
decreases the leak of albumin into the preterm lung and is 
therefore less injurious.
Lung inflammation and systemic activation of inflam-
mation follows tidal volume ventilation-induced stretch 
of immature lungs within 5–15 minutes after birth.41–43 
However, when low tidal volumes (5–9 mL/kg) are targeted 
and maintained throughout a 5-hour protocol, minimal 
lung inflammation, expressed as bronchoalveolar lavage 
fluid inflammatory cells, or expression of proinflammatory 
cytokines are found.10
Jaarsma et al demonstrated a drop in polymorphonuclear 
leukocytes (PMNs) within 5–10 minutes of birth in ventilated 
132-day premature lambs as a marker of inflammation.43 
Carlton et al described that circulating PMNs transiently 
disappeared from blood within 2 hours after birth due to 
sequestration in the lungs of preterm lambs (127 ± 1 days 
gestation) with RDS.44 They also found that the circulating 
PMN cell numbers returned to prenatal values by 6–8 hours 
after birth.44 The peptide-containing synthetic surfactant 
lucinactant, has recently been shown to be associated with 
less systemic (plasma IL [interleukin]-6 and IL-8) and lung 
inflammation (proinflammatory markers), better lung expan-
sion, and lower ventilator requirements than no surfactant 
treatment or treatment with porcine-and bovine-derived sur-
factants.34 We found that a systemic inflammatory response 
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as reflected by changes in PMNs was only detectable in the 
Curosurf® group, but although the total white blood cell count 
and neutrophil count in this group increased significantly 
between birth and 5 hours of life, it was no different from 
the values found in the other two groups at 5 hours. In both 
the saline- and Synsurf-treated groups, no significant changes 
in neutrophil counts or total white blood cell count occurred. 
Our findings are therefore in keeping with those described 
by Carlton et al, showing comparative PMNs and total white 
blood cell count numbers between cord blood (prenatal) 
and 5 hours of life.44 Furthermore, we found no relation-
ship between changes in neutrophil counts and PaO
2
/FiO
2
 
or PaCO
2
 respectively, in order to demonstrate an influence 
of systemic inflammation in the lung on gas exchange and a 
relationship with respiratory compromise. Moreover, there 
was no accumulation of alveolar macrophages or white blood 
cells in the alveoli of the animals that received Curosurf® 
or Synsurf (histology of saline-instilled lungs were similar 
to that of surfactant-treated lungs). Taken together with the 
findings of a relative lack of lung inflammation, we speculate 
that surfactant administration before first breath did not exert 
a clear anti-inflammatory protective effect, but possibly the 
initiation of ventilation utilizing a low tidal volume may 
have played a role.
Why did the Synsurf-treated animals have a more sus-
tained oxygenation response and significantly better PaO
2
/
FiO
2
 ratio at 300 minutes? Explanations may include earlier 
studies that have shown that clinical responses after surfactant 
treatment in experimental animals is unpredictable when 
based on in vitro (bench) properties, and surfactants behave 
differently with respect to loss from the lungs and sensitivity 
to soluble airway proteins.45,46 In other words, the surfactant 
with the best in vitro characteristics may not necessarily 
perform better than others in the preterm lamb model.
Conclusion
To conclude, treatment with surfactants before first breath 
clearly resulted in improved systemic oxygenation, with the 
response of Synsurf-treated animals being more sustained 
at 300 minutes. The functional importance of the synthetic 
peptide complex in Synsurf was therefore apparent from the 
results obtained with a control group and the group of lambs 
treated with an equivalent dosage of Curosurf®.
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